Related Experiment Videos
Pharmacokinetics of bendroflumethiazide
Clinical Pharmacology and Therapeutics
|October 1, 1977
Summary
Bendroflumethiazide (bft), a diuretic, was studied in healthy volunteers. The drug is rapidly absorbed, has a short half-life, and is primarily eliminated through nonrenal pathways.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Drug Metabolism
Background:
- Bendroflumethiazide is a commonly prescribed thiazide diuretic.
- Understanding its pharmacokinetic profile is crucial for effective therapeutic use.
Purpose of the Study:
- To characterize the pharmacokinetics of orally administered bendroflumethiazide in healthy volunteers.
- To determine key parameters including absorption, distribution, elimination, and routes of excretion.
Main Methods:
- Oral administration of 10 mg bendroflumethiazide to 9 healthy volunteers.
- Quantification of bendroflumethiazide concentrations in plasma and urine using gas-liquid chromatography (GLC).
- Calculation of pharmacokinetic parameters such as peak plasma levels, half-life, volume of distribution, and clearance.
Main Results:
- Peak plasma concentrations of bendroflumethiazide (86 +/- 18 ng/ml) were achieved at 2 +/- 0.4 hours.
- The mean elimination half-life (t1/2) was 3.0 hours, with an apparent volume of distribution of 1.48 L/kg.
- Nonrenal elimination predominated, with nonrenal clearance at 269 +/- 77 ml/min and renal clearance at 105 +/- 24 ml/min. Urinary recovery averaged 30%.
Conclusions:
- Bendroflumethiazide is rapidly absorbed and exhibits a relatively short elimination half-life.
- The primary route of bendroflumethiazide elimination is nonrenal, indicating significant hepatic or other non-kidney metabolism.
- These pharmacokinetic findings provide essential data for optimizing bendroflumethiazide dosing and understanding its disposition in healthy individuals.